Medication management
The AHA today submitted comments on the Food and Drug Administration’s Medical Device Safety Action Plan.
The Food and Drug Administration has approved special handling instructions to allow health care providers to use certain opioid and other intravenous drug products made by Hospira that were on hold due to low potential for a manufacturing defect but are in short supply.
The Food and Drug Administration today issued a final order exempting manufacturers from FDA premarket notification requirements for certain N95 respirators, disposable devices used to protect patients and health care providers from infection.
The Food and Drug Administration Friday issued final guidance clarifying that an organization may operate both a compounding pharmacy and outsourcing facility at the same address or general location if they are completely segregated by clearly identified boundaries.
April 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired prescription pills at sites throughout the country.
Health care providers should not use endoscope connectors labeled for use without reprocessing between patients because they carry a risk of cross-contamination, the Food and Drug Administration announced today.
Sixteen U.S. senators today urged the Department of Health and Human Services to take immediate action to reduce the price of naloxone – a drug that can be delivered via nasal mist or injection to temporarily suspend the effects of an overdose until emergency responders arrive.
The Food and Drug Administration yesterday announced a firmware update to reduce the risk of rapid battery depletion and address cybersecurity vulnerabilities in certain Abbott devices that provide pacing for slow heart rhythms and electrical shock or pacing to stop dangerously fast heart rhythms.
Premier Pharmacy Labs has voluntarily recalled several lots of injectable drug products, primarily opioid pain relievers, due to possible microbial contamination.
At the request of AHA and others, the Drug Enforcement Administration has taken steps that will address the IV opioid shortages.